$2.68
+0.04
(+1.52%)▲
3.36%
Downside
Day's Volatility :3.36%
Upside
0.0%
28.73%
Downside
52 Weeks Volatility :91.4%
Upside
87.94%
Period | An2 Therapeutics, Inc. | Index (Russel 2000) |
---|---|---|
3 Months | 13.79% | 0.0% |
6 Months | -86.46% | 0.0% |
1 Year | -67.69% | 0.0% |
3 Years | -82.86% | -20.2% |
Market Capitalization | 79.0M |
Book Value | $3.71 |
Earnings Per Share (EPS) | -2.51 |
Wall Street Target Price | 12.0 |
Profit Margin | 0.0% |
Operating Margin TTM | 0.0% |
Return On Assets TTM | -42.32% |
Return On Equity TTM | -68.38% |
Revenue TTM | 0.0 |
Revenue Per Share TTM | 0.0 |
Quarterly Revenue Growth YOY | 0.0% |
Gross Profit TTM | 0.0 |
Diluted Eps TTM | -2.51 |
Quarterly Earnings Growth YOY | 0.0 |
EPS Estimate Current Year | -2.43 |
EPS Estimate Next Year | -2.39 |
EPS Estimate Current Quarter | -0.62 |
EPS Estimate Next Quarter | -0.63 |
What analysts predicted
Upside of 347.76%
Sell
Neutral
Buy
An2 Therapeutics, Inc. is currently in a favorable trading position ( BUY ) according to technical analysis indicators.
Company Name | 1 Month | 6 Month | 1 Year | 3 Years | 5 Years |
---|---|---|---|---|---|
![]() An2 Therapeutics, Inc. | 25.12% | -86.46% | -67.69% | -82.86% | -82.86% |
![]() Moderna, Inc. | -1.67% | 18.26% | -0.21% | -64.15% | 752.69% |
![]() Regeneron Pharmaceuticals, Inc. | -0.46% | 13.21% | 45.59% | 84.19% | 244.2% |
![]() Novo Nordisk A/s | -11.0% | 18.31% | 61.56% | 186.46% | 423.59% |
![]() Vertex Pharmaceuticals Incorporated | 3.85% | 14.43% | 39.88% | 147.45% | 195.07% |
Company Name | P/E Ratio | P/B Ratio | PEG Ratio | EPS | ROE | ROA | Div Yield | BVPS |
---|---|---|---|---|---|---|---|---|
![]() An2 Therapeutics, Inc. | NA | NA | NA | -2.43 | -0.68 | -0.42 | NA | 3.71 |
![]() Moderna, Inc. | 24.73 | NA | 0.0 | -7.19 | -0.38 | -0.16 | NA | 33.47 |
![]() Regeneron Pharmaceuticals, Inc. | 31.35 | 31.35 | 1.46 | 44.44 | 0.15 | 0.08 | NA | 250.15 |
![]() Novo Nordisk A/s | 44.28 | 44.28 | 2.36 | 3.43 | 1.0 | 0.25 | 0.01 | 22.18 |
![]() Vertex Pharmaceuticals Incorporated | 31.85 | 31.85 | 0.53 | 16.98 | 0.24 | 0.13 | NA | 71.8 |
Company Name | Analyst View | Market Cap | 5 Years Return % | PE Ratio | Profit Margin |
---|---|---|---|---|---|
![]() An2 Therapeutics, Inc. | Buy | $79.0M | -82.86% | NA | 0.0% |
![]() Moderna, Inc. | Buy | $45.3B | 752.69% | 24.73 | -115.82% |
![]() Regeneron Pharmaceuticals, Inc. | Buy | $116.9B | 244.2% | 31.35 | 29.45% |
![]() Novo Nordisk A/s | Buy | $572.0B | 423.59% | 44.28 | 36.55% |
![]() Vertex Pharmaceuticals Incorporated | Buy | $126.7B | 195.07% | 31.85 | 39.46% |
Insights on An2 Therapeutics, Inc.
In the last 1 year, Novo Nordisk A/s has given 61.6% return, outperforming this stock by 129.3%
RA Capital Management, LLC
TCG Crossover Management, LLC
Bvf Inc
HHG PLC
Avidity Partners Management LP
Octagon Capital Advisors LP
an2 therapeutics, inc. is a california-based global health biopharmaceutical company focused on bringing the power of modern biomedical and drug development expertise to provide transformational medicines for patients suffering from infectious diseases. an2 is a mission-driven company, with a vision for humanity to be free from the threat of infectious diseases by addressing the urgent need for new treatments that can save lives across the globe. founded by a small team of biopharmaceutical industry leaders with a passion for global health and experience in infectious disease drug r&d, we strive to bring patients treatments that will restore their health and enable them to live productive lives.
Organization | An2 Therapeutics, Inc. |
Employees | 41 |
CEO | Mr. Joseph S. Zakrzewski |
Industry | Services |
Iheartmedia
$2.68
+1.52%
Gigacloud Technology Inc
$2.68
+1.52%
Qurate Retail Inc
$2.68
+1.52%
Madison Square Garden Entertainment Corp
$2.68
+1.52%
Xpel Inc
$2.68
+1.52%
Telecom Argentina S.a.
$2.68
+1.52%
Barrett Business Services Inc
$2.68
+1.52%
Stitch Fix, Inc. (class A Shares)
$2.68
+1.52%
Jack In The Box Inc.
$2.68
+1.52%